Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
